A methotrexate blood test measures how much methotrexate is still circulating in the blood after a dose. It is used most often after high-dose methotrexate chemotherapy, where the result helps doctors decide whether the drug is clearing safely or whether rescue treatment needs to be intensified. Methotrexate can be highly effective, but it depends heavily on kidney clearance. If levels stay high for too long, the risk of kidney injury, mouth sores, low blood counts, liver irritation, and other serious toxicity rises.
This test is different from the routine blood work used for weekly low-dose methotrexate in rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other inflammatory conditions. In those settings, clinicians usually monitor blood counts, liver enzymes, albumin, and kidney function rather than a methotrexate drug level. The result only makes sense when the dose, route, infusion time, kidney function, and exact blood draw time are known.
- A methotrexate blood level measures the drug concentration in serum or plasma, usually reported in micromoles per liter, written as µmol/L.
- The test is mainly used after high-dose methotrexate to check whether the drug is clearing from the body on schedule.
- A “safe” result is not one universal number; many protocols continue monitoring until the level is below about 0.05–0.1 µmol/L.
- High or slowly falling levels can mean delayed clearance, often from kidney stress, dehydration, acidic urine, drug interactions, or fluid collections.
- Weekly low-dose methotrexate usually requires CBC, liver, and kidney safety monitoring, not routine methotrexate level testing.
- Urgent symptoms while taking methotrexate include fever, mouth ulcers, unusual bruising or bleeding, severe diarrhea, shortness of breath, confusion, or reduced urination.
Table of Contents
- What the Methotrexate Blood Test Measures
- When the Test Is Ordered
- Timing, Sample Collection, and Preparation
- Therapeutic, Toxic, and Clearance Ranges
- How Results Are Interpreted
- Why Methotrexate Levels Can Stay High
- Toxicity Symptoms and Follow-Up Tests
- Questions to Ask About Your Result
What the Methotrexate Blood Test Measures
The methotrexate blood test measures the concentration of methotrexate in the liquid part of the blood. Most laboratories report the result in µmol/L. Some reports may use nmol/L; 1 µmol/L equals 1,000 nmol/L.
Methotrexate is an antifolate medicine. It interferes with folate pathways that cells use to make DNA and divide. At high doses, this effect can help treat certain cancers, including some leukemias, lymphomas, osteosarcoma, and central nervous system tumors. At much lower weekly doses, methotrexate can calm inflammation in conditions such as rheumatoid arthritis, psoriasis, and some autoimmune diseases.
The same medicine can therefore appear in very different clinical situations. A methotrexate blood level is most useful when the dose is high enough that delayed clearance could become dangerous. In high-dose cancer treatment, the medicine is expected to reach very high levels early, then fall in a predictable pattern as the kidneys remove it. The blood test shows whether that fall is happening quickly enough.
This test does not measure the full biological effect of methotrexate inside cells. It measures circulating drug in blood. That distinction matters because toxicity can sometimes continue even after the blood level has fallen, especially if the patient has severe mouth sores, low blood counts, kidney injury, or other complications.
Methotrexate level testing also differs from broader therapeutic drug monitoring. Some medicines have a stable therapeutic range used for long-term dose adjustment. Methotrexate levels after high-dose therapy are more like a timed clearance map. The question is not simply whether the number is “normal,” but whether it is appropriate for the exact hour after treatment.
When the Test Is Ordered
Methotrexate level testing is usually ordered after high-dose methotrexate, especially when the treatment plan includes leucovorin rescue. Leucovorin, also called folinic acid, helps protect normal cells from the antifolate effects of methotrexate. The dose and duration of leucovorin are often adjusted based on the methotrexate level and kidney function.
A clinician may order methotrexate levels to:
- Confirm that high-dose methotrexate is clearing on schedule
- Decide when leucovorin rescue can be reduced or stopped
- Detect delayed clearance before severe toxicity develops
- Guide extra hydration and urine alkalinization
- Help decide whether glucarpidase is needed in severe delayed clearance with kidney injury
- Monitor levels after treatment for overdose or accidental dosing errors
In weekly low-dose methotrexate treatment, routine methotrexate drug levels are usually not helpful. A person taking low-dose methotrexate for inflammatory disease may still need regular safety labs, but those labs usually include a complete blood count, liver enzymes, albumin, and kidney markers such as creatinine or eGFR. These tests look for bone marrow suppression, liver irritation, and reduced kidney clearance.
A methotrexate level may still be ordered in a low-dose patient if there is concern for severe overdose, accidental daily dosing, kidney failure, or serious toxicity. For example, a patient who mistakenly takes a weekly dose every day for several days may become very ill even if the blood level is not as high as levels seen during cancer treatment. In that situation, the clinician treats the patient, symptoms, blood counts, kidney function, and timing together rather than relying on the methotrexate level alone.
Methotrexate testing may also be part of a broader toxicology evaluation when the exposure history is unclear. In hospital settings, a toxicology blood test panel may be ordered alongside targeted drug levels when clinicians are sorting out overdose, poisoning, or mixed medication exposure.
Timing, Sample Collection, and Preparation
Methotrexate level timing is essential. A result without the collection time is hard to interpret because the expected level changes hour by hour after treatment. A level that is acceptable at 24 hours may be dangerous if it remains the same at 72 hours.
For high-dose methotrexate, blood levels are often checked at scheduled times such as 24, 48, and 72 hours after the start of the infusion, or according to the cancer center’s protocol. Some regimens use different draw times because the infusion length, dose, and diagnosis differ. Levels may then be repeated every 24 hours, or more often in urgent situations, until the drug reaches the protocol’s clearance threshold.
No special fasting is usually needed for the blood draw. The most useful preparation is accurate information. Tell the care team:
- The exact methotrexate dose and route, if known
- When the infusion started and ended, or when tablets were taken
- Whether any doses were missed, repeated, or taken on the wrong day
- All prescription medicines, over-the-counter drugs, and supplements
- Any kidney disease, reduced urination, vomiting, diarrhea, or dehydration
- Any recent antibiotics, anti-inflammatory medicines, or acid-reducing medicines
- Whether pregnancy is possible
The sample is usually taken from a vein. If the patient has an IV line or central line, the care team must avoid contamination from the methotrexate infusion. Drawing from a line used for methotrexate can falsely raise the result if the line is not handled correctly. When results do not match the patient’s condition, clinicians may repeat the test from a clean peripheral draw or a carefully prepared line.
During high-dose treatment, methotrexate testing is usually paired with strict fluid management. Patients often receive IV fluids and urine alkalinization to help keep methotrexate soluble and moving through the kidneys. Urine pH, fluid balance, creatinine, and sometimes electrolytes are followed closely. A kidney function blood test panel can show whether the kidneys are under stress while the methotrexate level is falling.
Therapeutic, Toxic, and Clearance Ranges
Methotrexate does not have one simple therapeutic range that applies to every patient. The meaning of the result depends on why methotrexate was given.
For high-dose methotrexate, early blood levels are expected to be high. The treatment is designed that way. The danger comes when the level stays high longer than expected. Many hospitals use timed nomograms that compare the patient’s level with the hour after infusion and the treatment protocol.
For low-dose weekly methotrexate, blood level testing usually does not guide routine dosing. A patient can have toxicity from dosing mistakes, kidney impairment, or drug interactions even when a single level is not easy to interpret. Safety monitoring is usually based on symptoms and labs that show organ effects.
| Result pattern | What it can mean | Typical clinical response |
|---|---|---|
| Undetectable or very low when no methotrexate was recently taken | No measurable circulating drug, or drug has already cleared | No action needed from the level alone, unless symptoms or other labs are abnormal |
| Falling as expected after high-dose treatment | Clearance is on schedule for that protocol | Continue planned leucovorin, fluids, urine alkalinization, and repeat levels until cleared |
| Higher than expected for the hour after infusion | Delayed clearance or increased toxicity risk | Increase rescue measures, review kidney function and interacting medicines, and monitor more closely |
| Persistently elevated with rising creatinine | Possible methotrexate-associated kidney injury with delayed elimination | Urgent oncology, nephrology, or toxicology management; glucarpidase may be considered in selected cases |
| Result after glucarpidase treatment | Some immunoassays may overestimate methotrexate because of metabolite interference | Use the laboratory method and clinical protocol specified by the treatment team |
Many treatment protocols aim for a level below about 0.05–0.1 µmol/L before stopping rescue therapy, but the exact cutoff varies. Some protocols use 0.05 µmol/L, some use 0.1 µmol/L, and some adjust the decision based on symptoms, kidney function, and the chemotherapy regimen.
General examples often used for high-dose methotrexate monitoring are levels around 10 µmol/L at 24 hours, 1 µmol/L at 48 hours, and 0.1 µmol/L at 72 hours. These numbers are not a substitute for the treating center’s protocol. A patient who received a longer infusion, a different dose, or a different cancer regimen may have a different expected curve.
Very high levels at later time points are more concerning when creatinine is rising. Creatinine is a waste product used to estimate kidney filtration. When creatinine increases after methotrexate, it can mean the kidneys are clearing the drug more slowly, which can further raise methotrexate exposure. This is why methotrexate levels and kidney markers are interpreted together rather than separately.
How Results Are Interpreted
A methotrexate result is interpreted with the dose, infusion duration, time of blood draw, kidney function, urine pH, hydration status, and symptoms. The number alone is not enough.
The first step is to confirm timing. A result reported as 1.2 µmol/L could be acceptable, borderline, or dangerous depending on whether it was drawn 24, 48, or 72 hours after treatment. Timing errors can lead to overtreatment or undertreatment, so oncology teams often document the exact hour after infusion.
The second step is to compare the result with the expected clearance curve. Methotrexate normally falls as the kidneys remove it. If the level drops steeply, rescue therapy may continue as planned. If the level falls slowly or plateaus, clinicians look for delayed clearance.
The third step is to check kidney function. Rising creatinine, reduced urine output, fluid retention, or abnormal electrolytes can change the plan quickly. Methotrexate can crystallize in kidney tubules, especially when urine is acidic or the patient is dehydrated. Once kidney function worsens, methotrexate clearance can slow further, creating a cycle of higher levels and more kidney stress.
The fourth step is to evaluate toxicity. Mouth sores, severe nausea, diarrhea, low blood counts, fever, infection, and bleeding can signal clinically important toxicity even while the level is being followed. The blood level helps guide rescue treatment, but symptoms and organ function decide urgency.
The fifth step is to review medicines that affect methotrexate clearance. Common examples include some nonsteroidal anti-inflammatory drugs, penicillins, sulfonamides, trimethoprim-sulfamethoxazole, proton pump inhibitors, probenecid, and salicylates. These drugs do not cause the same risk in every person, and some may be used safely in selected situations, but they deserve careful review when methotrexate levels are high or kidney function is changing.
After glucarpidase, interpretation becomes more specialized. Glucarpidase rapidly breaks down methotrexate in the bloodstream, but the breakdown product can interfere with some methotrexate immunoassays. This can make the reported level look higher than the true active methotrexate level. The care team may use a specific laboratory method or interpret results through a post-glucarpidase protocol.
Why Methotrexate Levels Can Stay High
High or slowly falling methotrexate levels usually mean the body is not clearing the drug as expected. The kidneys do most of the work of removing methotrexate, so anything that reduces kidney filtration or urine flow can raise risk.
Dehydration is one common factor. Vomiting, diarrhea, poor intake, fever, or inadequate IV fluids can reduce urine output. When less urine moves through the kidneys, methotrexate can become more concentrated. High-dose protocols use aggressive hydration partly to prevent this problem.
Acidic urine can also contribute. Methotrexate is less soluble in acidic urine, which increases the chance that it can precipitate in kidney tubules. Urine alkalinization helps keep the drug dissolved so it can pass through the kidneys more safely.
Kidney impairment before treatment raises risk as well. A patient with reduced eGFR, older age, kidney disease, dehydration, or prior kidney injury may clear methotrexate more slowly. This is why baseline creatinine and eGFR are checked before high-dose therapy. If creatinine rises during treatment, the team may adjust leucovorin, fluids, urine alkalinization, and monitoring frequency.
Fluid collections can delay clearance. Pleural effusions, ascites, and other “third-space” fluid collections can act like reservoirs. Methotrexate may move into these spaces and then leak back into the bloodstream later, prolonging exposure. In some patients, these fluid collections are drained or managed before high-dose methotrexate is given.
Drug interactions can slow clearance or increase toxicity. Some antibiotics, anti-inflammatory medicines, acid suppressants, and kidney-affecting drugs can interfere with methotrexate handling. The risk depends on the methotrexate dose, kidney function, hydration, and the specific interacting medicine. Patients should not stop prescribed medicines on their own, but they should make sure the oncology, rheumatology, dermatology, or primary care team has a complete medication list.
Dosing mistakes are a separate cause of toxicity, especially with low-dose methotrexate. Many patients take methotrexate once weekly, not daily. Taking it every day by mistake can cause dangerous mouth ulcers, low blood counts, infection, liver injury, kidney stress, and gastrointestinal symptoms. In that situation, clinicians may check a methotrexate level, but the more urgent information often comes from the CBC, kidney function, liver enzymes, and the patient’s symptoms.
Toxicity Symptoms and Follow-Up Tests
Methotrexate toxicity can affect several parts of the body. Some symptoms are mild and expected during treatment, while others need urgent medical attention. The safest approach is to report new or worsening symptoms promptly, especially after high-dose therapy or a dosing mistake.
Urgent symptoms include:
- Fever, chills, or signs of infection
- Painful mouth sores or ulcers
- Unusual bruising, bleeding, nosebleeds, or black stools
- Severe or persistent nausea, vomiting, or diarrhea
- Shortness of breath, dry cough, or chest discomfort
- Reduced urination, swelling, or sudden weight gain
- Confusion, severe headache, seizure, or new weakness
- Widespread rash, peeling skin, or painful skin changes
- Yellowing of the skin or eyes
Follow-up testing depends on the situation. In high-dose methotrexate, the drug level is repeated until clearance is adequate. Creatinine, BUN, electrolytes, urine pH, and fluid balance are often monitored closely. A creatinine and eGFR pattern helps show whether delayed clearance is tied to kidney function.
Blood counts are also important. Methotrexate can suppress the bone marrow, causing low white blood cells, anemia, or low platelets. Low white blood cells raise infection risk, while low platelets raise bleeding risk. A CBC with differential can show whether the marrow is recovering or worsening.
Liver tests may be checked because methotrexate can raise liver enzymes. This is especially relevant with long-term low-dose therapy, alcohol use, liver disease, obesity-related fatty liver, viral hepatitis, or other medicines that affect the liver. A liver function tests panel may include ALT, AST, alkaline phosphatase, bilirubin, albumin, and related markers depending on the lab.
For severe delayed clearance, treatment may include higher-dose leucovorin, continued IV hydration, urine alkalinization, stopping interacting medicines, and specialized rescue therapy. Glucarpidase may be used in selected patients with high methotrexate levels and kidney injury after high-dose methotrexate. Dialysis is not the main solution for most cases, but kidney specialists may be involved when kidney failure, fluid overload, or electrolyte problems are serious.
Patients taking weekly low-dose methotrexate need a different monitoring mindset. The main safety checks are routine labs and symptom awareness. A stable patient may have scheduled monitoring every few weeks at the start and then less often once stable, depending on the condition, dose, risk factors, and local guidance. New kidney problems, medication changes, infections, or abnormal labs may require more frequent monitoring.
Questions to Ask About Your Result
A methotrexate level is most useful when you understand the timing and the plan attached to it. Patients and caregivers can ask direct, practical questions that make the result easier to follow.
Useful questions include:
- What was my methotrexate level, and what unit was used?
- How many hours after the dose or infusion was this sample drawn?
- Is the level falling as expected for my treatment protocol?
- What level does my team want before stopping leucovorin or discharge monitoring?
- Is my creatinine or eGFR changing?
- Do I need more IV fluids, urine alkalinization, or a change in leucovorin dose?
- Are any of my medicines slowing methotrexate clearance?
- Are my CBC and liver tests safe?
- What symptoms should make me call right away?
- When is the next level being checked?
For high-dose methotrexate, ask whether your result is being compared with your specific protocol rather than a generic range. High-dose regimens can differ by cancer type, dose, infusion length, age, kidney function, and supportive care plan.
For weekly low-dose methotrexate, ask which safety labs you need and how often. Also confirm the dosing schedule in plain language. Many prescriptions are written as a weekly dose, such as “take once every 7 days.” Because accidental daily dosing can be dangerous, it helps to use a calendar, pill organizer, or written medication list that clearly marks the methotrexate day.
For any methotrexate use, ask whether folic acid or folinic acid is part of your plan. Folic acid is often used with low-dose methotrexate to reduce side effects. Leucovorin rescue is used in specific high-dose or toxicity settings. These are related but not interchangeable in every situation.
A single methotrexate result can look alarming without context. The safest interpretation comes from the full pattern: the dose, the hour drawn, whether the number is falling, kidney function, urine output, symptoms, and the treatment protocol. When those pieces are put together, the test can guide timely rescue care and help prevent avoidable toxicity.
References
- Preventing and Managing Toxicities of High-Dose Methotrexate 2016 (Review)
- Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance 2018 (Guideline)
- Methotrexate monitoring 2024 (Guidance)
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis 2021 (Guideline)
- Methotrexate 2024 (Patient Drug Information)
Disclaimer
Methotrexate levels and safety labs must be interpreted by a qualified clinician who knows the dose, timing, kidney function, and treatment protocol. Do not change, skip, or repeat methotrexate based only on a lab result without medical guidance. Seek urgent care for fever, severe mouth sores, unusual bleeding, severe diarrhea, shortness of breath, confusion, reduced urination, or suspected methotrexate dosing mistakes.
